DS-70, a novel and potent α integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs.

Background And Purpose: Allergic conjunctivitis is an eye inflammation that involves the infiltration of immune cells into the conjunctiva via cell surface-adhesion receptors, such as integrin α β . These receptors interact with adhesion molecules expressed on the conjunctival endothelium and may be a target to treat this disease. We synthesized DS-70, a novel α/β-peptidomimetic α integrin antagonist, to prevent the conjunctival infiltration of immune cells and clinical symptoms in a model of allergic conjunctivitis.

Experimental Approach: In vitro, DS-70 was pharmacologically characterized using a scintillation proximity procedure to measure its affinity for α β integrin, and its effect on cell adhesion mediated by different integrins was also evaluated. The effects of DS-70 on vascular cell adhesion molecule-1 (VCAM-1)-mediated degranulation of a human mast cell line and an eosinophilic cell line, which both express α β , and on VCAM-1-mediated phosphorylation of ERK 1/2 in Jurkat E6.1 cells were investigated. Effects of DS-70 administered in the conjunctival fornix of ovalbumin-sensitized guinea pigs were evaluated.

Key Results: DS-70 bound to integrin α β with nanomolar affinity, prevented the adhesion of α integrin-expressing cells, antagonized VCAM-1-mediated degranulation of mast cells and eosinophils and ERK 1/2 phosphorylation. Only 20% was degraded after an 8 h incubation with serum. DS-70 dose-dependently reduced the clinical symptoms of allergic conjunctivitis, conjunctival α integrin expression and conjunctival levels of chemokines and cytokines in ovalbumin-sensitized guinea pigs.

Conclusions And Implications: These findings highlight the role of α integrin in allergic conjunctivitis and suggest that DS-70 is a potential treatment for this condition.